NCT03795922: A trial that was reported late by Medy-Tox
This trial has reported, although it was 80 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03795922 |
|---|---|
| Title | A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 24, 2018 |
| Completion date | March 13, 2020 |
| Required reporting date | March 13, 2023, midnight |
| Actual reporting date | June 1, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 80 |